HASBROUCK HEIGHTS, N.J., Oct. 31, 2011 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that a presentation on the long-term results of NX-1207 treatment for benign prostatic hyperplasia (BPH) was given at the North Eastern Section of the American Urological Association by Dr. Barrett E. Cowan on Friday afternoon in New Orleans. Dr. Cowan, of Denver, CO, gave a moderated poster presentation at 3:36 p.m. (Central time) on Friday, October 28 with data from U.S. patients given NX-1207 in the past 7 years.
The presentation was authored by Neal Shore MD FACS, of Myrtle Beach, SC, Sheldon Freedman MD FACS, of Las Vegas, NV, Barton Wachs, MD FACS, of Long Beach, CA and Barrett Cowan, MD FACS, of Denver, CO. All four co-authors are distinguished Board-certified urologists with clinical expertise and extensive knowledge as clinical investigators in FDA-regulated clinical trials, including the NX-1207 clinical trials.
NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. Follow-up studies have shown evidence of long lasting benefit with a significant proportion of men who received a single dose reporting maintained improvement in BPH symptoms without other treatments for up to 7½ years.
BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age.
More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.